[December 18, 2014] |
|
Research and Markets: Human Papillomavirus Infections - Pipeline Review, H1 2014
Research and Markets (http://www.researchandmarkets.com/research/dzj28q/human)
has announced the addition of the "Human
Papillomavirus Infections - Pipeline Review, H1 2014" report to
their offering.
This report provides comprehensive information on the therapeutic
development for Human Papillomavirus Infections, complete with
comparative analysis at various stages, therapeutics assessment by drug
target, mechanism of action (MoA), route of administration (RoA) and
molecule type, along with latest updates, and featured news and press
releases. It also reviews key players involved in the therapeutic
development for Human Papillomavirus Infections and special features on
late-stage and discontinued projects.
Drug profiles/records featured in the report undergo periodic updation
following a stringent set of processes that ensures that all the
profiles are updated with the latest set of information. Additionally,
processes including live news & deals tracking, browser based alet-box
and clinical trials registries tracking ensure that the most recent
developments are captured on a real time basis.
Reasons to buy
-
Provides strategically significant competitor information, analysis,
and insights to formulate effective R&D development strategies
-
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
-
Develop strategic initiatives by understanding the focus areas of
leading companies
-
Identify and understand important and diverse types of therapeutics
under development for Human Papillomavirus Infections
-
Plan mergers and acquisitions effectively by identifying key players
of the most promising pipeline
-
Devise corrective measures for pipeline projects by understanding
Human Papillomavirus Infections pipeline depth and focus of Indication
therapeutics
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope
-
Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline
Companies Mentioned:
-
Merck & Co
-
Takeda Pharmaceutical Company
-
MediGene
-
Chong Kun Dang Pharmaceutical
-
Crucell
-
Starpharma Holdings
-
Bharat Biotech International
-
FluGen
-
BioMAS
-
ApoVax
-
Genticel
-
Genetic Immunity
-
Vaxart
-
IRX Therapeutics
-
Selecta Biosciences
-
Spider Biotech
-
EyeGene
-
Indian Immunologicals
-
Beijing Minhai Biotechnology
-
Coridon
-
Chongqing Zhifei Biological Products
-
Redbiotec
-
Agilvax
For more information visit http://www.researchandmarkets.com/research/dzj28q/human
[ Back To TMCnet.com's Homepage ]
|